Should I buy or sell ProPhase Labs stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRPH shares. View PRPH analyst ratings or view top-rated stocks .

What is ProPhase Labs' stock price target for 2024?

1 brokers have issued 1 year price targets for ProPhase Labs' shares. Their PRPH share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 78.7% from the stock's current price. View analysts price targets for PRPH or view top-rated stocks among Wall Street analysts .

How have PRPH shares performed in 2024?

ProPhase Labs' stock was trading at $4.52 at the beginning of the year. Since then, PRPH stock has increased by 36.2% and is now trading at $6.1550. View the best growth stocks for 2024 here .

When is ProPhase Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PRPH earnings forecast .

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by $0.33. The company earned $9.47 million during the quarter, compared to analyst estimates of $9.08 million. ProPhase Labs had a negative net margin of 37.81% and a negative trailing twelve-month return on equity of 29.83%. During the same quarter in the previous year, the business posted ($0.05) EPS.

What is Ted Karkus' approval rating as ProPhase Labs' CEO?

2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com . Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ProPhase Labs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS) , Sorrento Therapeutics (SRNE) , CymaBay Therapeutics (CBAY) , Rigel Pharmaceuticals (RIGL) , SCYNEXIS (SCYX) , Bausch Health Companies (BHC) , Fulcrum Therapeutics (FULC) , Novus Therapeutics (NVUS) , Onconova Therapeutics (ONTX) and Recro Pharma (REPH) .

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRPH

ProPhase Labs (PRPH) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free PRPH Stock Alerts

$6.93

+0.77 (+12.50%)

(As of 11:36 AM ET)

Compare

Today's Range: $6.27
▼
$7.06
50-Day Range: $4.47
▼
$6.89
52-Week Range: $4.05
▼
$9.94

Volume: 87,542 shs
Average Volume: 28,050 shs
Market Capitalization: $125.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get ProPhase Labs alerts:

ProPhase Labs MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 78.7% Upside
$11.00 Price Target
Short Interest: Bearish
1.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.15
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.24 out of 5 stars

Medical Sector

785th out of 928 stocks

Pharmaceutical Preparations Industry

370th out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
ProPhase Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ProPhase Labs has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
1.83% of the float of ProPhase Labs has been sold short.
Short Interest Ratio / Days to Cover
ProPhase Labs has a short interest ratio ("days to cover") of 9.6.
Change versus previous month
Short interest in ProPhase Labs has recently increased by 3.67%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
ProPhase Labs does not currently pay a dividend.
Dividend Growth
ProPhase Labs does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRPH.

1.6

News and Social Media Coverage

News Sentiment
ProPhase Labs has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for ProPhase Labs this week, compared to 1 article on an average week.
Search Interest
7 people have searched for PRPH on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ProPhase Labs insiders have not sold or bought any company stock.
Percentage Held by Insiders
26.10% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.45% of the stock of ProPhase Labs is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of ProPhase Labs is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ProPhase Labs is -6.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ProPhase Labs has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About ProPhase Labs Stock (NASDAQ:PRPH)

ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

PRPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRPH Stock News Headlines

April 16, 2024 | globenewswire.com

ProPhase Labs Unveils Project ZenQ-AI

April 10, 2024 | finanznachrichten.de

ProPhase Labs, Inc.: ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 10, 2024 | baystreet.ca

ProPhase Flat on Cancer Drug Progress

April 10, 2024 | globenewswire.com

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024

April 1, 2024 | globenewswire.com

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2024 | finance.yahoo.com

ProPhase Labs, Inc. (PRPH)

March 18, 2024 | finance.yahoo.com

ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call Transcript

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 15, 2024 | msn.com

PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023

March 15, 2024 | globenewswire.com

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

March 14, 2024 | benzinga.com

ProPhase Labs's Earnings: A Preview

March 12, 2024 | msn.com

Down 34% and 57%, Wall Street Says These 2 Stocks Will Gain 230%

March 8, 2024 | globenewswire.com

PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024

March 1, 2024 | finance.yahoo.com

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 29% Above Their Intrinsic Value Estimate

February 21, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Prophase Labs (PRPH) and Crispr Therapeutics AG (CRSP)

February 21, 2024 | finance.yahoo.com

Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

February 20, 2024 | finance.yahoo.com

ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

February 20, 2024 | finance.yahoo.com

ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

February 16, 2024 | finance.yahoo.com

PRPH Mar 2024 5.000 put

February 15, 2024 | markets.businessinsider.com

Buy Rating for Prophase Labs on Strong Clinical Trial Results and Manufacturing Expansion

February 14, 2024 | finanznachrichten.de

ProPhase Labs, Inc.: ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir

February 14, 2024 | finance.yahoo.com

ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir

February 14, 2024 | globenewswire.com

ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir

February 8, 2024 | finance.yahoo.com

Diamond Equity Research Releases In Depth Update Note on ProPhase Labs, Inc. (NASDAQ: PRPH) subsidiary, Pharmaloz Manufacturing, Inc. (PMI)

January 30, 2024 | baystreet.ca

ProPhase Dips on Moving Karkus up Ladder

January 30, 2024 | finance.yahoo.com

ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics

See More Headlines

Receive PRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PRPH
CUSIP: N/A
CIK: 868278
Web: www.prophaselabs.com
Phone: (215) 345-0919
Fax: 215-345-5920
Employees: 129
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +78.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,780,000.00
Net Margins: -37.81%
Pretax Margin: -51.37%
Return on Equity: -29.83%
Return on Assets: -18.14%

Debt

Debt-to-Equity Ratio: 0.29
Current Ratio: 2.28
Quick Ratio: 2.10

Sales & Book Value

Annual Sales: $44.38 million
Price / Sales: 2.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.74 per share
Price / Book: 2.25

Miscellaneous

Outstanding Shares: 18,050,000
Free Float: 13,335,000
Market Cap: $111.10 million
Optionable: Optionable
Beta: -0.29

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Ted William Karkus (Age 65)
Chairman & CEO
Comp: $902.2k
Mr. Jed A. Latkin (Age 50)
Chief Operating Officer & Head of Finance Department
Mr. Robert A. Morse Jr. (Age 49)
Controller, Principal Financial Officer & Principal Accounting Officer
Mr. Sergio Miralles
Executive VP & Chief Information Officer
Mr. Jason Karkus
President of Nebula Genomics
Mr. Kamal Obbad
Senior VP and Director of Sales & Marketing - Nebula Genomics

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PRPH Stock Analysis - Frequently Asked Questions

Should I buy or sell ProPhase Labs stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRPH shares.
View PRPH analyst ratings or view top-rated stocks.
What is ProPhase Labs' stock price target for 2024?: 1 brokers have issued 1 year price targets for ProPhase Labs' shares. Their PRPH share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 78.7% from the stock's current price.
View analysts price targets for PRPH or view top-rated stocks among Wall Street analysts.
How have PRPH shares performed in 2024?: ProPhase Labs' stock was trading at $4.52 at the beginning of the year. Since then, PRPH stock has increased by 36.2% and is now trading at $6.1550.
View the best growth stocks for 2024 here.
When is ProPhase Labs' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PRPH earnings forecast.

How were ProPhase Labs' earnings last quarter?: ProPhase Labs, Inc. (NASDAQ:PRPH) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by $0.33. The company earned $9.47 million during the quarter, compared to analyst estimates of $9.08 million. ProPhase Labs had a negative net margin of 37.81% and a negative trailing twelve-month return on equity of 29.83%. During the same quarter in the previous year, the business posted ($0.05) EPS.
What is Ted Karkus' approval rating as ProPhase Labs' CEO?: 2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of ProPhase Labs own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH).
How do I buy shares of ProPhase Labs?: Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRPH) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial